Mathew Mathai, MD
Pulmonary Disease · Cudahy, WINPI 1104854363
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,685 of the $28,338 with a category attached, or 76.5%. Boehringer Ingelheim accounts for 78.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $17,129 and has fallen 99.6% since, to $64 in 2025. Among pulmonary disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $223.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$22K
- Mylan Specialty L.p.$5K
- AstraZeneca$357
- Genentech USA, Inc.$239
- Baxter Healthcare$189
- GSK$165
- plus $620 from 11 others
Across 7 payments — averaging $10,225 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$47K
- Mylan Specialty L.p.$25K
What the payments were for
- Consulting fees$3,32112%
- Speaking & faculty fees$21,68577%
- Travel & lodging$9493%
- Food & beverage$2,2058%
- Education$1781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 23 | $22,163 |
| Mylan Specialty L.p. | 10 | $4,605 |
| AstraZeneca | 8 | $357 |
| Genentech USA, Inc. | 10 | $239 |
| Baxter Healthcare | 4 | $189 |
| GSK | 19 | $165 |
| Philips North America LLC | 23 | $137 |
| Insmed, Inc. | 4 | $124 |
| Sunovion Pharmaceuticals Inc. | 13 | $111 |
| Jazz Pharmaceuticals Inc. | 4 | $85 |
| CSL Behring | 2 | $49 |
| Sanofi | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Harmony Biosciences LLC | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,338 in reported general payments places this provider in the 90th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 471 | $411,558 |
| ZemairaAlpha-1-Proteinase Inhibitor | 15 | $119,221 |
| Breo ElliptaFluticasone/Vilanterol | 151 | $100,266 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 150 | $91,348 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $48,958 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $48,280 |
| Spiriva RespimatTiotropium Bromide | 66 | $46,336 |
| Spiriva HandihalerTiotropium Bromide | 52 | $32,464 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $25,844 |
| XolairOmalizumab | 11 | $17,687 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 114 | $14,532 |
| Roflumilast | 116 | $13,806 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 432 | $11,586 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $8,235 |
| Advair DiskusFluticasone Propion/Salmeterol | 35 | $7,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $165 | $603,172772 claims |
| CSL BehringZemaira | $49 | $119,22115 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $22,163 | $103,529137 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $357 | $74,124123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Cudahy
- Paul LisiCudahy$12K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.